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Abstract  70	
Objective To determine the risk of stroke associated with subclinical hypothyroidism. 71	
Data Sources and Study Selection Published prospective cohort studies were identified through 72	
a systematic search through November 2013 without restrictions in several databases. 73	
Unpublished studies were identified through the Thyroid Studies Collaboration. We collected 74	
individual participant data (IPD) on thyroid function and stroke outcome. Euthyroidism was 75	
defined as thyrotropin (TSH) levels 0.45-4.49 mIU/L, subclinical hypothyroidism as TSH levels 76	
4.5-19.9 mIU/L with normal thyroxin levels.  77	
Data Extraction and Synthesis We collected IPD on 47,573 adults (3451 subclinical 78	
hypothyroidism) from 17 cohorts, followed-up 1972-2014 (489,192 person-years). Age- and sex-79	
adjusted pooled hazard ratio (HR) for participants with subclinical hypothyroidism compared to 80	
euthyroidism was 1.05 (95% CI, 0.91-1.21) for stroke events (combined fatal and non-fatal 81	
stroke) and 1.07 (95% CI, 0.80-1.42) for fatal stroke. Stratified by age, the HR for stroke events 82	
was 3.32 (95% CI, 1.25-8.80) for individuals aged 18-49 years. There was an increased risk of 83	
fatal stroke in the age groups 18-49 and 50-64 years with a HR of 4.22 (95% CI, 1.08-16.55) and 84	
2.86 (95% CI, 1.31-6.26), respectively (p trend 0.04). We found no increased risk for those 65-79 85	
years (HR 1.00, 95% CI, 0.86-1.18) or ≥80 years (HR 1.31, 95% CI, 0.79-2.18). There was a 86	
pattern of increased risk of fatal stroke with higher TSH concentrations. 87	
Conclusions Although no overall effect of subclinical hypothyroidism on stroke could be 88	
demonstrated, an increased risk in subjects younger than 65 years and those with higher TSH 89	
concentrations was observed.		90	
	91	
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Introduction 92	
Subclinical hypothyroidism is defined as an elevated thyrotropin (TSH) level above the upper 93	
limit of the reference range with a free thyroxin (FT4) value that is normal (1-3). It has a 94	
prevalence varying between 4-14% in adults (4-6) with a higher prevalence in iodine-sufficient 95	
populations (7) and older individuals (5). Subclinical hypothyroidism has been associated with 96	
hypercholesterolemia (6, 8, 9), atherosclerosis (10), and an increased carotid intima-media 97	
thickness (IMT ) (11). Furthermore, the association between subclinical hypothyroidism and risk 98	
of clinical cardiovascular outcomes such as coronary heart disease (12) and heart failure (13), 99	
has been established in specific subgroups with higher TSH levels (12). Also, higher risks of 100	
cardiovascular disease (CVD) in subclinically hypothyroid individuals have been found in 101	
younger populations but not in the oldest old (14, 15). 102	
Although CVD and stroke share risk factors, published data on the association between 103	
subclinical hypothyroidism and stroke are insufficient and conflicting (16). Even the largest 104	
prospective cohort studies have limited power, with most studies suffering from lack of 105	
generalizability and inability to conduct subgroup analyses on specific age groups or different 106	
TSH levels (17-19). A recent systematic review and meta-analysis of published data showed no 107	
association between subclinical hypothyroidism and the risk of stroke (16). However, meta-108	
analysis of aggregated published data does not always allow for examination of specific 109	
subgroups that may have differential risk. Hence, we aimed to evaluate the association between 110	
subclinical hypothyroidism and stroke by conducting an individual participant data (IPD) 111	
analysis, with pre-specified stratified analyses to examine the effects of age, sex and degree of 112	
TSH elevation on this association.  113	
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Materials and Methods 114	
Data Sources and Study Selection 115	
We conducted a systematic review and meta-analysis, contacted experts in the field and reviewed 116	
reference lists to identify eligible studies (16). The systematic literature search was conducted in 117	
Medline (OvidSP), EMBASE, Web-of-science, PubMed publisher, Cochrane and Google 118	
Scholar from inception to the 18th of November 2013 (Supporting Information). We included 119	
publications from longitudinal studies that measured at least TSH and (F)T4 at baseline in adults 120	
and assessed stroke events and/or fatal stroke prospectively. Further details of the systematic 121	
literature search and meta-analysis have been previously described in detail elsewhere (16). We 122	
identified six studies (17-22) that met the inclusion criteria. We identified additional studies with 123	
unpublished data within the Thyroid Studies Collaboration (TSC), a consortium of cohort studies 124	
investigating the association between thyroid dysfunction and clinical outcomes. Through 125	
contact with experts in the field, we were able to identify one more unpublished study (23). 126	
Investigators from eligible studies were invited to join the IPD analysis, of which one declined to 127	
participate (22).	This study included 549 euthyroid subjects with 23 stroke events and 31 128	
subclinical hypothyroid subjects with 1 stroke event. 129	
 130	
Data Extraction 131	
We requested individual participant characteristics related to prior cardiovascular risk factors and 132	
disease, including total cholesterol, systolic blood pressure (both as continuous variables), 133	
history of diabetes, smoking and previous cerebrovascular disease. We also collected available 134	
information on medication use (thyroid hormone replacement, anti-thyroid, lipid-lowering and 135	
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anti-hypertensive therapy), demographic information (age, sex and ethnicity), anthropometric 136	
measurements (height and weight) and the outcome. Primary outcome measures were stroke 137	
events (fatal and non-fatal) and fatal stroke. Stroke was defined according to World Health 138	
Organization (WHO) criteria as a syndrome of rapidly developing clinical signs of focal (or 139	
global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to 140	
death, with no apparent cause other than of vascular origin, including ischemic or hemorrhagic 141	
strokes. Some studies (24, 25) used variations of this definition (Supplemental Table 1).  142	
 143	
Thyroid Function Testing 144	
We used a common definition of subclinical hypothyroidism and euthyroidism in order to 145	
increase comparability between the different studies and in concordance with previous analyses 146	
(12, 13, 26), expert reviews (1, 3) and several large cohorts (17, 25, 27). We defined subclinical 147	
hypothyroidism as a serum TSH level of 4.5 mIU/L or greater to less than 20.0 mIU/L, with a 148	
normal (free) T4 concentration. Euthyroidism was defined as TSH level between 0.45 and 4.49 149	
mIU/L. Most studies used a third-generation TSH radioimmunoassay, but the Whickham Survey 150	
used a first-generation assay that reports higher measured TSH values than current assays,(28) 151	
for which we adjusted the range to 6.0 – 21.4 mIU/L to define subclinical hypothyroidism, as 152	
previously described (12, 29). In addition the Whickham Survey was the only study to perform 153	
total T4 assays (29); the remainder performed free T4 (FT4) assays.  154	
For (F)T4 values, we used site- and method-dependent cutoffs, as these measurements are more 155	
assay dependent. We excluded participants with TSH levels below 0.45 mIU/L or above 19.9 156	
mIU/L and those with abnormal (F)T4 values (n=3967). When (F)T4 values were missing (n= 157	
10,541), we considered participants with a TSH level between 4.5 and 20 mIU/L as having 158	
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subclinical hypothyroidism, due to a low likelihood of overt hypothyroidism with this degree of 159	
TSH elevation (30).  160	
 161	
Statistical Analysis 162	
We performed a Cox proportional hazard model in each cohort separately to assess the 163	
association between subclinical hypothyroidism and stroke events and fatal stroke (IBM SPSS 164	
Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp). The Cox-proportional hazard 165	
assumption was met by each cohort, as assessed by Schoenfeld residual plots. We used a 166	
random-effects model according to DerSimonian and Laird(31) to pool estimates of the 167	
outcomes. Pooled estimates were summarized in forest plots using the metafor package for R (R-168	
project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, version 169	
3.0.2). Heterogeneity across studies was measured using the I2 statistic and tested using the Q-170	
statistic (32). 171	
We adjusted for age and sex in the primary analysis. We also conducted a multivariable analysis 172	
additionally adjusting for systolic blood pressure, smoking, total cholesterol and diabetes. These 173	
covariates were available in all cohorts except for the Birmingham cohort (21). We conducted 174	
multiple imputation in cohorts when there was ≥ 5% of missing data for the smoking, total 175	
cholesterol, systolic blood pressure and prevalent diabetes covariates. We considered the age and 176	
sex adjusted analysis the primary analysis because 1 ) covariates used in the multivariable 177	
analyses could also be considered as mediators 2) it includes all studies in contrast to the 178	
multivariable analysis that does not include the Birmingham cohort.  179	
In order to identify populations at risk and possible sources of heterogeneity, we conducted pre-180	
defined subgroup and sensitivity analyses. We performed stratified analyses by age, sex and 181	
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degree of TSH elevation. Based on expert reviews (1, 3) and following our previous approach 182	
(12, 13) we stratified subclinical hypothyroidism into the following TSH categories: 4.5-6.9 183	
mIU/L, 7.0-9.9 mIU/L and 10.0-19.9 mIU/L. If a study did not have an event in the (stratified) 184	
study-specific analysis, we used Firth's penalized maximum likelihood bias reduction method for 185	
the Cox model (33, 34) to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).  186	
We conducted the following sensitivity analyses: 1) excluding three (20, 23, 35) studies that did 187	
not have stroke events (non-fatal and fatal) in the subclinical hypothyroidism group 2) excluding 188	
participants who had thyroid-function altering medication at baseline and during follow-up 3) 189	
excluding studies that included transient ischemic attack (TIA) as a stroke event 4) excluding 190	
participants with a history of stroke 5) excluding participants with missing (F)T4 levels 6) using 191	
only unimputed data 7) cohorts with potential co-morbidities and 8) including the published risk 192	
estimates of the study that declined to participate in the meta-analysis (22). We assessed age- and 193	
sex-adjusted funnel plots and conducted Egger tests (36) to evaluate potential publication bias.  194	
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Results 195	
We found 18 prospective cohort studies that met the criteria. From these we included 17 from the 196	
United States (17, 19, 35), Europe (15, 20, 21, 23, 24, 27, 29, 37-40), Australia (25), Brazil (41) 197	
and Japan (18) that prospectively assessed stroke outcomes and agreed to share individual 198	
participant data (Table 1, Supplemental Figure 1). One study (42) was excluded from our 199	
analyses because no outcome events occurred. The included studies provided information on a 200	
total of 47,573 participants with a follow-up from 1972 to 2014, a median follow-up ranging 201	
between 1.5 and 20 years and a total follow-up of 489,192 person-years. All studies, except one 202	
(43, 44), included both female (50.8%) and male participants. The prevalence of subclinical 203	
hypothyroidism ranged from 0.4 to 16.3%, with an overall average of 7.3% (n= 3451) of which 204	
62% were female. All cohorts reported fatal stroke and 12 studies also reported stroke events, 205	
including fatal and non-fatal stroke, contributing to the stroke events analysis among 37,842 206	
participants. During follow-up 2547 stroke events occurred and 1014 participants had a fatal 207	
stroke.  208	
All studies provided information on the proportion of participants taking thyroid medication at 209	
baseline, which varied from 0 to 8.7%. All but five studies also provided follow-up information 210	
on thyroid function-altering medication use, with a range between 0 and 12.6%. One study(24) 211	
used questionnaires for the assessment of stroke events. Formal adjudication, defined as having 212	
clear criteria for the outcomes that were reviewed by experts for each potential case, was used 213	
for stroke events in six studies (10, 15, 17, 19, 22, 40) and for fatal stroke in two additional 214	
studies (35, 39). Three studies (18, 35, 39) required multiple imputation due to more than 5% 215	
missing data for covariates. 216	
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The age- and sex-adjusted pooled HR for participants with subclinical hypothyroidism compared 217	
to euthyroidism was 1.05 (95% CI, 0.91-1.21) for stroke events and 1.07 (95% CI, 0.80-1.42) for 218	
fatal stroke (Figure 1). We found no heterogeneity for the stroke events analysis (I2=0%) and 219	
little heterogeneity for fatal stroke (I2=25%). 220	
Subsequent subgroup analyses showed an increased risk of stroke events (HR 3.32, 95% CI, 221	
1.25-8.80) and fatal stroke (HR 4.22, 95% CI, 1.08-16.55) in the 18-49 year age group with 222	
subclinical hypothyroidism compared to euthyroidism, but the number of events was small 223	
(Table 2, Figure 2). For the 50-64 year age group, we found an increased risk of fatal stroke with 224	
a HR of 2.86 (95% CI, 1.31-6.26), p for trend across age groups = 0.04. When participants were 225	
pooled into two categories, younger and older than 65 years, in a post-hoc analysis, we found a 226	
significantly increased risk of fatal stroke with a HR of 2.51 (95% CI, 1.42-4.44) in the younger 227	
group, p for interaction = 0.003 (Table 2). When looking at incidence rate per 100,000 person-228	
years for stroke events in the pooled dataset within each age group we find 58 for the18-49 year 229	
age group, 330 for the 50-64 year group, 1127 for the 65-79 group and 2991 for those 80 years 230	
and older. For fatal stroke this was 11, 74, 370 and 1183 per 100,000 person-years for the 231	
respective age groups. 232	
There was a non-significant pattern of increased risk of fatal stroke with higher TSH 233	
concentrations. In the age- and sex-adjusted analyses, the HR for fatal stroke was 1.18 (95% CI, 234	
0.83-1.69) in participants with TSH levels between 4.5 and 6.9 mIU/L, 1.63 (95% CI, 1.09-2.43) 235	
for those with TSH levels between 7.0 and 9.9 mIU/L, and 1.69 (95% CI, 0.88-3.27) for those 236	
with TSH levels between 10.0 and 19.9 mIU/L, compared to the euthyroid group (p for trend 237	
0.07). There was no observed difference by sex (p for interaction > 0.5). 238	
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Multivariable analyses, adjusting for sex, age, smoking, total cholesterol, systolic blood pressure 239	
and history of diabetes yielded similar results, with the exception of fatal stroke analysis in the 240	
age group between 50 and 65 years of age, which was attenuated after adjustment (Table 2). This 241	
was likely due to eliminating heterogeneity in this subgroup, with an I2 of 29% in the age- and 242	
sex-adjusted analysis and 0% in the multivariable analysis. 243	
Sensitivity analyses excluding several studies, excluding thyroid medication users, using only 244	
non-imputed data, additional adjustments and other sensitivity analyses did not meaningfully 245	
affect the risk estimates (Supplemental Table 2). We found no evidence of publication bias, 246	
either with visual assessment of age- and sex-adjusted funnel plots or with the Egger test for 247	
stroke events (p = 0.67) or fatal stroke (p = 0.58).   248	
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Discussion 249	
In our IPD analysis of 47,573 participants from 17 prospective cohort studies, no overall effect 250	
of subclinical hypothyroidism was observed on the risk of stroke events or fatal stroke compared 251	
to euthyroidism in age- and sex-adjusted analyses. However, younger participants had an 252	
increased risk of stroke events and fatal stroke in subclinical hypothyroidism compared to 253	
euthyroidism. There was an increase in fatal stroke in those younger than 65 years and in 254	
participants with a TSH level of 7.0 to 9.9 mIU/L, but a non-significant p for trend (0.07). This is 255	
the first IPD analysis to investigate the association between subclinical hypothyroidism and 256	
stroke. We are also the first to detect differences by age in associations between subclinical 257	
hypothyroidism and a clinical outcome in an IPD analysis. 258	
The mechanisms by which subclinical hypothyroidism increases the risk of stroke, as found in 259	
specific subgroups, could be explained by the increased prevalence of cardiovascular risk factors 260	
in those with subclinical hypothyroidism. Thyroid hormones have direct effects on the 261	
cardiovascular system and are known to decrease systemic vascular resistance (45) and alter 262	
systolic and diastolic cardiac function (46). Thyroid hormone deficiency increases the risk of 263	
several cardiovascular risk factors including hypertension (47), dyslipidemia (48) and 264	
atherosclerosis(49). These changes have also been observed in subclinical thyroid 265	
dysfunction(10, 50). However, our multivariable IPD analyses yielded similar results to the age- 266	
and sex-adjusted analyses. Adjusting for smoking, total cholesterol, systolic blood pressure and 267	
diabetes only slightly changed the risk estimates in the age-stratified analysis of fatal stroke for 268	
participants between 50 and 65 years old. The fact that adjustment for traditional cardiovascular 269	
risk factors did not substantially alter risk estimates suggests an independent association of 270	
subclinical hypothyroidism on the risk of stroke and also indicates that total cholesterol, systolic 271	
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blood pressure and diabetes are not relevant factors mediating the hypothetical pathway between 272	
subclinical hypothyroidism and stroke. Another explanation might be that this is due to some 273	
unmeasured confounders or mediators.  274	
Various abnormalities in the hemostatic system have been reported in overt (51, 52) and 275	
subclinical hypothyroidism(53-55). Alterations in coagulability and the fibrinolytic system have 276	
been linked to a high risk of CVD (56). This might also be one of the mechanisms that play a 277	
role in the increased risk of stroke in subclinical hypothyroidism. We were not able to 278	
discriminate between haemorragic and ischemic stroke in the current study as most cohorts did 279	
not collect these data. Another pathway linked with both thyroid function and risk of stroke is 280	
atrial fibrillation (26). This however, seems unlikely as atrial fibrillation is linked to overt and 281	
subclinical hyperthyroidism and not to hypothyroidism (26). The exact mechanistic relationship 282	
between subclinical hypothyroidism and the risk of stroke still remains to be determined. 283	
In our study, younger individuals with subclinical hypothyroidism had a higher risk of stroke 284	
events and fatal stroke compared with euthyroid subjects within the same age groups. Although a 285	
higher risk in those younger than 65 years of age has previously been reported in a meta-analysis 286	
of published data studying the association between subclinical thyroid disease and coronary heart 287	
disease(57), this was not confirmed by an IPD analysis investigating the same association(12). 288	
Several population based studies and published data meta-analysis found an association between 289	
subclinical hypothyroidism and various clinical outcomes, including self-reported health (58), 290	
ischemic heart disease (14, 18, 29, 57) and cognition (15) when including younger age groups 291	
but not in older populations. However, these differences in association by age have not been 292	
observed in IPD analyses prior to ours.  293	
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In our IPD-analysis, the relationship between subclinical hypothyroidism and the risk of stroke 294	
seen in younger individuals does not seem to hold in populations of 65 years and older. This 295	
seems counterintuitive as both the prevalence and incidence of subclinical hypothyroidism and 296	
stroke are higher in elderly than in younger populations. An explanation for the absence of the 297	
association in elderly subjects could be that adverse outcomes of subclinical hypothyroidism 298	
(e.g. hyperlipidemia) are leveled out in this particular group due to slowing of metabolic rate and 299	
energy expenditure (59), reduced sensitivity to adrenergic stimulation (60) or other 300	
counterbalancing protective factors. Also, differences in stroke etiology in younger versus older 301	
individuals could explain the difference in risk estimates by age group. For example, stroke in 302	
younger adults is more often hemorrhagic compared to older individuals (61). Subclinical and 303	
overt hypothyroidism are linked to hypocoagulability (51) and could through this pathway have a 304	
stronger effect on younger adults rather than on the elderly. There might also be the possibility of 305	
competing risk of events in the elderly. However, this rarely leads to meaningful changes in 306	
relative risk estimates of the hazard ratio (62). Another possible explanation for the different 307	
risks across age groups might be a changed hypothalamus-pituitary-thyroid set point in elderly, 308	
leading to higher TSH levels (63, 64). In this case subclinical hypothyroidism, defined with a 309	
TSH > 4.5 mIU/L may not reflect thyroidal status as well as in younger individuals (65-67) and 310	
subclinical hypothyroidism and stroke would exist simultaneously rather than have a causal 311	
relation in those older than 65 years of age. It is debated whether age-specific reference ranges 312	
are needed to define the normal range and herewith also the altered state of thyroid function. 313	
Some studies have found relevant reclassification of thyroid status by applying age-specific 314	
reference ranges of TSH (68), while others have not (69). The question remains whether the 315	
definition of the normal range should be based on age-specific biochemical cut-offs or rather 316	
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based on risk of clinical adverse events associated with these cut-offs. The findings of our study 317	
suggest that for older subjects a TSH cut-off higher than 4.5 ImU/L could be applied, while this 318	
cut-off might be too high for younger individuals. However, further studies are needed to 319	
determine the risks and benefits of redefining the cut-offs of thyroid function.  320	
We found a higher risk of fatal stroke in a subset of subclinically hypothyroid individuals with 321	
TSH levels between 7.0 and 9.9 mIU/L, when compared to individuals with values within the 322	
TSH reference range. We were not able to demonstrate an association for the subgroup with a 323	
TSH level between 10.0 and 19.9 mIU/L, which is probably due to lack of power, as the point 324	
estimate for fatal stroke was higher than for TSH levels between 7.0 and 9.9 mIU/ml, suggesting 325	
a dose-response relationship.  326	
The strengths of our study is that we were able to perform an IPD analysis including over 47,000 327	
participants from 17 cohort studies, based on published and unpublished data. We did an 328	
extensive literature search and included all available published data on the association between 329	
subclinical hypothyroidism and the risk of stroke and fatal stroke. Furthermore we were able to 330	
find additional cohorts with unpublished longitudinal data with information on thyroid function 331	
and stroke outcomes. One of the advantages of performing an IPD analysis is that it enables the 332	
standardization of the definition of exposures and covariates used for the time-to-event analyses, 333	
allowing a more uniform interpretation. Although we found similar overall results in this IPD 334	
analysis compared to the previous study-level meta-analysis (16), we did observe additional 335	
important findings in subgroups that were not detected by meta-analyzing the aggregate data. 336	
This highlights the strength of an IPD analysis, as it provides a better opportunity for subgroup 337	
and sensitivity analyses. 338	
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Despite the large number of participants, we had limited power mainly for the stratified analyses. 339	
Power calculations showed that our study had a statistical power of 80% to detect a HR of 1.57 340	
for stroke events and a HR of 1.61 for stroke mortality. The power was limited especially in the 341	
age subgroup analyses under 50 where the number of events was decreased, reflected in the wide 342	
confidence intervals. There were also limited numbers of events in those with TSH levels 343	
between 10.0 and 19.9 mIU/L. Information on thyroid medication use during follow-up, which 344	
could alter risk over time, was not available for some cohorts. We were unable to perform 345	
analyses stratified by type of stroke (ischemic vs. hemorrhagic) due to limited number of events 346	
in each stratum or by race due to having few non-white participants. Furthermore, thyroid 347	
function was determined only at baseline in most cohorts and therefore it was not possible to take 348	
the evolution of thyroid dysfunction over time into account. As a number of participants with 349	
mildly elevated TSH levels will normalize in the course of time, a second measurement of 350	
thyroid function would have enabled us to specifically investigate participants with persistent 351	
subclinical hypothyroidism, where perhaps the effects are more pronounced. 352	
In summary we found no association between subclinical hypothyroidism and overall risk of 353	
stroke events or fatal stroke. In stratified analyses, younger participants, particularly those under 354	
the age of 50 years, had increased stroke risk, though the number of events was small. Those 355	
with TSH of 7.0-9.9 mIU/L also had an increased risk of fatal stroke compared to their euthyroid 356	
counterparts. Our data are reassuring for those over the age of 65 years and those with TSH 357	
levels between 4.5 and 6.9 mIU/L, who represent the majority of participants with subclinical 358	
hypothyroidism. Whether treatment of subclinical hypothyroidism will result in a decrease of 359	
risk of stroke in younger subjects or those with higher TSH levels needs to be answered by a 360	
sufficiently powered randomized clinical trial. 361	
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Legend of Figures 621	
Figure 1.  The Risk of Stroke Events and Fatal Stroke in Subclinical Hypothyroidism 622	
versus Euthyroidisma 623	
 624	
a Hazard ratios (HRs) and their 95% confidence intervals (CIs) are 625	
represented by squares. Sizes of data markers are proportional to the inverse 626	
of the variance of the hazard ratios.  627	
b Data for stroke events were available in 12 studies. Three hundred eighty-628	
seven participants were excluded from the analysis of stroke event due to 629	
missing follow-up data. 630	
c Data for fatal stroke were available in 17 studies. Three hundred twenty-631	
nine participants were excluded from the analysis of fatal stroke, due to 632	
missing cause of death.  633	
 634	
Figure 2.  Hazard Ratios (HRs) for Stroke Events and Fatal Stroke for Subclinical 635	
Hypothyroidism Stratified by Age vs Euthyroidism and According to 636	
Elevated Thyroid–Stimulating Hormone (TSH) Categoriesa 637	
 638	
a Hazard ratios (HRs) and their 95% confidence intervals (CIs) are 639	
represented by squares. Sizes of data markers are proportional to the inverse 640	
of the variance of the hazard ratios. Unfilled squares indicate the reference 641	
categories. For the analysis stratified by age, HRs for stroke events and fatal 642	
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stroke were adjusted for sex and age as a continuous variable to avoid 643	
residual confounding within age strata. 644	
b Data for stroke events were available in 12 studies. Three hundred eighty-645	
seven participants were excluded from the analysis of stroke event due to 646	
missing stroke event data.  647	
c Data for fatal stroke were available in 17 studies. Three hundred twenty-648	
nine participants were excluded from the analysis of fatal stroke, due to 649	
missing cause of death.  650	
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 47,573) 
Study, Start year Description of Study Sample No. Median Age (Range), yearsa 
Women No. 
(%) 
Subclinical 
Hypothyroidism 
No. (%) 
Thyroid 
Medication 
No. (%) at 
baselineb 
Thyroid 
Medication 
No. (%) 
follow upc 
Median 
Duration (IQR), 
years 
4D Study20, 1998 
Trial of atorvastatin in type 2 
diabetes and hemodialysis patients, 
Germany 
883 66 (30-83) 400 (45.3) 10 (1.1) 44 (5.0) 62 (7.0) 1.5 (0.2-3.6) 
Brazilian Thyroid 
Study41, 1999 
Adults from Japanese descent living 
in São Paulo, Brazil 991 57 (30-92) 523 (52.8) 101 (10.2) 0 NA 7.3 (7.0-7.5) 
Busselton Health 
Study25, 1981 
Adults in Busselton, Western 
Australia 2001 51 (18-90) 984 (49.2) 89 (4.4) 15 (0.7) 33 (1.6) 20 (19.5-20.0) 
Birmingham 
Study21, 1988 
CDA's aged ≥ 60 y from primary care 
practice in Birmingham, England 1107 69 (60-94) 628 (56.7) 92 (8.3) 0 29 (2.6) 10.2 (5.7-10.6) 
Cardiovascular 
Health Study17, 
1989  
CDA’s with Medicare eligibility in 4 
US communities 3017 71 (64-100) 1812 (60.1) 492 (16.3) 0 153 (5.1) 13.9 (8.6-16.4) 
EPIC-Norfolk 
Study27, 1995 Adults living in Norfolk, England 12709 58 (40-78) 6874 (54.1) 723 (5.7) 0 NA 13.4 (12.6-14.3) 
Health, Aging, and 
Body Composition 
Study19, 1997 
CDA’s with Medicare eligibility in 2 
US communities 2677 74 (69-81) 1346 (50.3) 335 (12.5) 232 (8.7) 338 (12.6) 11.9 (7.5-12.2) 
InCHIANTI 
Study37, 1998 
Adults aged 20-102 years living in 
Chianti geographic area, Italy 1099 71 (21-102) 612 (55.7) 33 (3.0) 21 (1.9) NA 9.07 (8.1-9.2) 
Leiden 85-plus 
Study15, 1997 
Adults aged 85 years living in 
Leiden, The Netherlands 493 85 (NA) 322 (65.3) 35 (7.1) 14 (2.8) 20 (4.1) 5.2 (2.5-8.6) 
MrOS Study35, 
2000 
Community-dwelling U.S. men aged 
65 years and older 1558 73 (65-99) 0 148 (9.5) 110 (7.1) NA 12.0 (8.2-12.7) 
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 47,573) (continued) 
Study, Start year Description of Study Sample No. Median Age (Range), yearsa 
Women No. 
(%) 
Subclinical 
Hypothyroidism 
No. (%) 
Thyroid 
Medication 
No. (%) at 
baselineb 
Thyroid 
Medication 
No. (%) 
follow upc 
Median 
Duration (IQR), 
years 
Nagasaki Adult 
Health Study18, 
1984 
Atomic bomb survivors in Nagasaki, 
Japan 2766 57 (38-92) 1688 (61.0) 424 (15.3) 39 (1.4) 6 (0.2) 13.0 (12.3-13.6) 
Pisa cohort39, 2000 Patients admitted to cardiology department in Pisa, Italyd 2922 63 (19-92) 935 (32.0) 227 (7.8) 12 (0.4) 0 2.5 (1.6-3.7) 
PREVEND 
Study23, 1997 
Adults living in Groningen, The 
Netherlands 2562 46 (28-75) 1306 (51) 51 (2.0) 27 (1.1) 34 (1.3) 10.9 (10.6-11.1) 
PROSPER trial40, 
1997 
Trial on the benefits of pravastatin vs. 
placebo in adults  5525 75 (69-83) 2801 (50.7) 446 (8.1) 211 (3.8) 264 (4.8) 3.3 (3.0-3.5) 
Rotterdam Study10, 
38, 1989 
Adults ≥55 years living in Rotterdam, 
The Netherlands 1697 68 (55-93) 1036 (61.0) 104 (6.1) 30 (1.8) NA 16.8 (11.1-18.9) 
SHIP Study24, 1997 Adults in West Pomerania, North-East of Germany 3118 47 (20-81) 1587 (50.9) 13 (0.4) 159 (5.1) 214 (6.9 11.3 (10.6-11.8) 
Whickham 
Survey29, 1972 
Adults living in & near Newcastle 
upon Tyne, England 2448 46 (18-92) 1308 (54.4) 128 (5.2) 99 (4.0)  71 (2.9) 19 (15.0-20.0) 
Overall  47,573 65 (18-102) 24,162 (50.8) 3451 (7.3) 1103 (2.3) 1224 (2.6) 11.6 (5.0-13.8) 
Abbreviations: CDA = community-dwelling adult; IQR = interquartile range (25th-75th percentile); NA = not available.  
a Participants younger than 18 years of age were not included 
b Participants with missing information on thyroid medication at baseline: CHS 1, HABC 7, Whickham 3, RS 482, MrOS 64 
c Participants with missing information on thyroid medication at follow-up: Birmingham 1026, Whickham 1489 
d Excluded patients with acute coronary syndrome or severe illness 
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Table 2. Stratified Analyses for the Associations between Subclinical Hypothyroidism and the Risk of Stroke and Fatal Stroke 
  
Stroke eventsa Fatal Strokeb 
 
  
No. events/ 
Total 
participants 
Age & sex 
adjusted  
HR (95% CI) 
Multivariablec  
HR (95% CI) 
No. events/ 
Total 
participants 
Age & sex 
adjusted  
HR (95% CI) 
Multivariablec 
HR (95% CI) 
Total Population 2547/37,842 1.05 (0.91, 1.21) 0.97 (0.77, 1.22) 1014/47,244 1.07 (0.80, 1.42) 1.11 (0.82, 1.50) 
 
Mend 1177/17,644 1.12 (0.88, 1.42) 1.07 (0.90, 1.27) 452/23,238 1.19 (0.83, 1.70) 1.19 (0.82, 1.72) 
 
Womend 1370/20,198 1.07 (0.90, 1.27) 1.17 (0.92, 1.49) 562/24,006 1.19 (0.86, 1.64) 1.24 (0.83, 1.84) 
 
p for interaction 
 
0.76 0.55 
 
0.99 0.88 
Agee 18 – 49y 64/8555 3.32 (1.25, 8.80) 3.34 (1.18, 9.46) 14 / 9,879 4.22 (1.08, 16.55) 4.80 (1.03, 22.30) 
 
50 – 64y 381/9723 1.34 (0.65, 2.80) 1.34 (0.69, 2.62) 117/13,289 2.86 (1.31, 6.26) 1.99 (1.05, 3.74) 
 
65 -79y 1803/17,611 1.00 (0.86, 1.18) 1.02 (0.87, 1.20) 698/21,460 1.07 (0.83, 1.39) 1.09 (0.82, 1.45) 
 
≥80 299/1953 1.31 (0.79, 2.18) 1.43 (0.93, 2.18) 185/2,616 1.23 (0.74, 2.04) 1.34 (0.75, 2.40) 
 
p for trend 
 
0.07 0.11 
 
0.04 0.08 
Agee 18-64y 445/18,278 1.37 (0.71, 2.63) 1.46 (0.78, 2.73) 131/23,168 2.51 (1.42, 4.44) 2.29 (1.41, 3.74) 
 ≥65y 2102/19,564 1.04 (0.90, 1.20) 1.03 (0.71, 1.49) 883/24,076 0.99 (0.81, 1.21) 1.04 (0.81, 1.32) 
 p for interaction  0.42 0.35  0.003 0.005 
TSH, mIU/L 0.45 - 4.49 2301 / 35,250 reference reference 910 / 43,648 reference reference 
 4.5 - 6.9 161 / 1799 1.01 (0.86, 1.19) 1.01 (0.85, 1.19) 72 / 2544 1.18 (0.83, 1.69) 1.09 (0.71, 1.67) 
 7.0 - 9.9 53 / 507 1.62 (0.89, 2.94) 1.68 (0.91, 3.09) 22 / 699 1.63 (1.09, 2.43) 1.65 (1.16, 2.33) 
 10.0 - 19.9 32 / 286 1.27 (0.90, 1.80) 1.26 (0.89, 1.79) 10 / 353 1.69 (0.88, 3.27) 1.79 (0.88, 3.63) 
 p for trend  0.05 0.05  0.07 0.05 
Abbreviations: CI, confidence interval; HR, hazard ratio; TSH, thyroid-stimulating hormone. 
a Data were available from 12 studies, 387 participants were excluded due to missing stroke event data. 
b 329 participants were excluded due to missing data on cause of death.  
c Adjusted for sex, age, systolic blood pressure, smoking and prevalent diabetes at baseline. The Birmingham Study was excluded in this 
analysis because of lack of data on cardiovascular risk factors. 
d These analyses were not adjusted for sex. 
e These HRs were adjusted for sex and age as continuous variable to avoid residual confounding within age strata. 
 
 
